A Qualified Clinical Data Registry can do one thing an ordinary registry cannot: write its own quality measures and get Medicare to approve them. For a specialty whose outcomes appear nowhere in the standard measure inventory, that single difference decides whether wound care clinicians report on the care they actually deliver or on somebody else’s.
What CMS means by a Qualified Clinical Data Registry
A QCDR is a third-party intermediary approved to submit data to CMS on a clinician’s behalf. CMS defines it as an entity that demonstrates clinical expertise in medicine and in quality measurement development, and that collects medical or clinical data to track patients and diseases. The requirements are structural rather than aspirational. Clinicians must be on staff and lending that expertise to the registry’s work. Where a QCDR relies on an outside organization for data collection or transmission, a signed collaboration agreement must predate the performance period by months — for 2026, it had to be in place before September 2, 2025.
The distinction that matters most sits in the guide CMS publishes for clinicians choosing an intermediary. A qualified registry submits measures that already exist. A QCDR may develop and support up to 30 CMS-approved QCDR measures — a set available only through a QCDR, which may include specialty-specific or disease-process measures absent from the MIPS quality measures inventory. Neither type submits for the cost category; CMS calculates that from claims. Both must give participants feedback at least four times a year. And approval expires annually: a registry that reported last year is not a registry this year until it self-nominates again and CMS re-approves it.
Why the distinction matters more in wound care than in most specialties
The MIPS quality inventory is built around measures broadly applicable across medicine. That works reasonably well for primary care and for specialties large enough to have driven measure development. It works poorly for a physician whose clinic day consists of debridement, offloading, compression, and vascular assessment, and whose performance is judged on measures written for conditions seen elsewhere.
The consequence is not merely cosmetic. Quality scores are public and they move payment. And the categories a clinician cannot report on still get calculated — as Caroline Fife has examined in the question of whether the EHR a physician uses affects the Cost category, the parts of MIPS a practice does not control shape the final score anyway. The QCDR route is the only mechanism by which a specialty can put its own outcomes into the part of the score it does control.
The measures wound care got, and who wrote them
The US Wound Registry publishes the eight wound care measures CMS approved for 2026: nutritional assessment and intervention planning; non-invasive arterial assessment for healing potential; adequate compression at each visit for venous leg ulcers; diabetic foot ulcer healing or closure; venous leg ulcer healing or closure; adequate offloading at each visit; pressure ulcer healing or closure; and objective measurement of wound surface area using AI-based imaging. They were developed in conjunction with the Alliance of Wound Care Stakeholders, the Undersea and Hyperbaric Medical Society, and the American Podiatric Medical Association.
Reading the archive of that page tells a second story. The 2023 set included a measure on appropriate use of hyperbaric oxygen therapy for diabetic foot ulcers and a patient-reported outcome for late effects of radiation. Neither appears in 2026. QCDR measures are re-nominated and re-approved each year, and the inventory a specialty relies on can contract as readily as it grows.
Outcome measures are a documentation problem first
Four of the eight are outcome or per-visit process measures. Healing and closure require wound surface area captured comparably at every encounter across an episode. Adequate compression and adequate offloading require an affirmative record at each visit, not a narrative that implies it happened. A note that reads well to a human reviewer but produces no discrete fields cannot produce a denominator, and a denominator is what reporting consists of.
This is the same underlying constraint that makes episode-based cost measurement difficult in this specialty, a problem Fife has followed in detail through the non-pressure ulcer cost measure now in field testing. Structured capture at the point of care, and a running quality scorecard that shows performance before the submission window closes, are what turn an approved measure into a reported one.
What the 2027 proposed rule would change
CMS issued the CY 2027 Physician Fee Schedule proposed rule on July 14, 2026. Two proposed Quality Payment Program changes for 2027 bear directly on this. CMS proposes to sunset traditional MIPS after the CY 2028 performance period, making MIPS Value Pathways the primary reporting route for clinicians outside APMs. It also proposes to require QCDRs and qualified registries to support at least six quality measures, including one MIPS core measure, beginning with the CY 2027 performance period.
Neither proposal is final, and both are worth commenting on. Read together, they suggest that specialty measures will increasingly sit alongside required core measures rather than replace them — which raises rather than lowers the value of an intermediary that already holds approved measures in the specialty and knows how to get them through self-nomination each year.
What a wound center should take from this
A QCDR is not a reporting convenience. It is the only mechanism in the Quality Payment Program through which a specialty can define what good care looks like in its own terms and have Medicare accept the definition. Wound care has eight such definitions for 2026 because a registry and three clinical organizations did the work of building and defending them, annually, against a process that assumes nothing carries over.
